Anika Therapeutics (ANIK) 46.92 $ANIK SmarTrend
Post# of 273318
Posted On: 09/26/2016 3:17:08 AM
Anika Therapeutics (ANIK) 46.92 $ANIK
SmarTrend Watching for Potential Rebound in Shares of Anika Therapeutics After 2.17% Loss
Comtex SmarTrend(R) - Fri Sep 23, 4:10PM CDT
Anika Therapeutics (NASDAQ:ANIK) traded in a range yesterday that spanned from a low of $46.62 to a high of $47.91. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $46.84 on volume of 57,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ANIK: 46.92 (-1.07)
Ligand Inks CNS License Agreement with Seelos Therapeutics
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:03AM CDT
Ligand Pharmaceuticals Incorporated (LGND) announced that it has granted licensing rights to four of its pipeline programs to Seelos Therapeutics, Inc.
CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), LGND: 115.78 (-2.38), ANIK: 46.92 (-1.07)
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:01AM CDT
Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC.
PFE: 34.26 (+0.11), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66), NVS: 81.48 (-0.55)
Anika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society
BusinessWire - Thu Sep 22, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced four data presentations on HYALOFAST, a biodegradable HA-based scaffold, at the 13th World Congress of the International Cartilage Repair Society (ICRS). The ICRS World Congress, which is being held in Sorrento, Naples, Italy during September 24-27, 2016, is the world's largest gathering of scientists, clinicians and industry participants focused on clinical cartilage repair and basic cartilage research.
ANIK: 46.92 (-1.07)
The Medicines Co. to Get BARDA Funding for Infection Drugs
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:29AM CDT
The Medicines Company (MDCO) announced a new strategic partnership with the Biomedical Advanced Research and Development Authority under which the company will receive funding for developing of new infection drug.
CBM: 46.60 (+0.30), MDCO: 40.45 (-1.05), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Gilead to Stop GS-5745 Development for Ulcerative Colitis
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 6:51AM CDT
Gilead Sciences (GILD) announced that it will discontinue the combined phase II/III study on GS-5745 in patients with ulcerative colitis.
GILD: 81.37 (-0.15), BMY: 56.48 (+0.06), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66)
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 2:08PM CDT
Regeneron (REGN) and Teva have inked a deal for the development and commercialization of experimental NGF antibody, fasinumab, for chronic pain.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), ANIK: 46.92 (-1.07), REGN: 410.39 (+2.38)
Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:51AM CDT
Puma Biotechnology (PBYI) announced that its New Drug Application for neratinib has been accepted for review by the FDA.
ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07), PBYI: 68.08 (+2.10)
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:47AM CDT
Amgen, Inc. (AMGN) announced positive top-line results from a phase III study evaluating the effect of its cholesterol-lowering medication, Repatha (evolocumab) on coronary artery disease (CAD) patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AMGN: 174.80 (-0.82), ANIK: 46.92 (-1.07)
Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 3:16PM CDT
Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.
VICL: 3.25 (+0.06), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
BioDelivery Bunavail Gets Better Managed Care Positioning
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:42AM CDT
BioDelivery Sciences International, Inc. (BDSI) has secured improved positioning for Bunavail (buprenorphine and naloxone) under three new managed care contracts.
BDSI: 2.70 (+0.25), CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:13AM CDT
Sarepta (SRPT) announced that it gained an accelerated approval for its Duchenne muscular dystrophy (DMD) drug, Exondys 51 (eteplirsen), in the U.S.
BMRN: 97.40 (-0.05), ANIP: 66.64 (-0.17), SRPT: 57.83 (-3.14), ANIK: 46.92 (-1.07)
Bayer (BAYRY) Strives for Increased Sales & Earnings Growth
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:09AM CDT
Bayer (BAYRY) has set out encouraging growth and earnings targets across all its businesses at the "Meet Management" investor conference.
MON: 103.50 (-0.70), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Celgene Presents Efficacy & Safety Phase II Ozanimod Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 5:53AM CDT
Celgene (CELG) reported efficacy and safety data at 2 years from the phase II RADIANCE study on ozanimod in relapsing multiple sclerosis patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07), CELG: 109.43 (-1.14)
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:26AM CDT
Ligand Pharmaceuticals Incorporated (LGND) announced that it has entered into a worldwide license agreement with California-based TeneoBio, Inc.
EBS: 28.36 (-0.38), ANIP: 66.64 (-0.17), LGND: 115.78 (-2.38), ANIK: 46.92 (-1.07)
Qiagen: Molecular Diagnostics & Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:14AM CDT
On Sep 13, 2016, we issued an updated research report on Qiagen NV (QGEN).
HSKA: 54.46 (-0.22), ANIP: 66.64 (-0.17), QGEN: 26.66 (-0.21), ANIK: 46.92 (-1.07)
Novavax Tanks, RSV F Vaccine Disappoints in Two Studies
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
Novavax (NVAX) announced disappointing top-line data from a couple of studies on RSV F Vaccine in older adults.
ANIP: 66.64 (-0.17), NVAX: 2.26 (+0.11), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07)
Teva/Intel Tie up for Huntington's Disease Technology Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:01AM CDT
Teva (TEVA) is collaborating with Intel (INTC) to develop a wearable device and machine learning platform that can be used for the treatment of Huntington's disease.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), INTC: 37.19 (-0.36), ANIK: 46.92 (-1.07)
Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 4:29PM CDT
Spectrum Pharmaceuticals' (SPPI) bladder cancer treatment Qapzola receives unfavorable recommendation from the FDA's advisory panel; stock down.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), SPPI: 4.72 (-0.09), ANIK: 46.92 (-1.07)
Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 9:27AM CDT
GlaxoSmithKline (GSK) reported that phase III study (ZOE-70) data on shingles vaccine candidate, Shingrix, were published in the New England Journal of Medicine.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), GSK: 43.42 (-0.16), ANIK: 46.92 (-1.07)
SmarTrend Watching for Potential Rebound in Shares of Anika Therapeutics After 2.17% Loss
Comtex SmarTrend(R) - Fri Sep 23, 4:10PM CDT
Anika Therapeutics (NASDAQ:ANIK) traded in a range yesterday that spanned from a low of $46.62 to a high of $47.91. Yesterday, the shares fell 2.2%, which took the trading range below the 3-day low of $46.84 on volume of 57,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
ANIK: 46.92 (-1.07)
Ligand Inks CNS License Agreement with Seelos Therapeutics
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:03AM CDT
Ligand Pharmaceuticals Incorporated (LGND) announced that it has granted licensing rights to four of its pipeline programs to Seelos Therapeutics, Inc.
CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), LGND: 115.78 (-2.38), ANIK: 46.92 (-1.07)
Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
Zacks Equity Research - Zacks Investment Research - Fri Sep 23, 9:01AM CDT
Novartis (NVS) announced positive top-line data from the phase III ASCEND-4 study on Zykadia to treat patients with ALK+ NSCLC.
PFE: 34.26 (+0.11), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66), NVS: 81.48 (-0.55)
Anika Announces Data Presentations on HYALOFAST Hyaluronic Acid-Based Scaffold at 2016 World Congress of the International Cartilage Repair Society
BusinessWire - Thu Sep 22, 3:05PM CDT
Anika Therapeutics, Inc., (NASDAQ: ANIK), a global, integrated orthopedics medicines company specializing in therapeutics based on its proprietary hyaluronic acid ("HA"
technology, today announced four data presentations on HYALOFAST, a biodegradable HA-based scaffold, at the 13th World Congress of the International Cartilage Repair Society (ICRS). The ICRS World Congress, which is being held in Sorrento, Naples, Italy during September 24-27, 2016, is the world's largest gathering of scientists, clinicians and industry participants focused on clinical cartilage repair and basic cartilage research. ANIK: 46.92 (-1.07)
The Medicines Co. to Get BARDA Funding for Infection Drugs
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 8:29AM CDT
The Medicines Company (MDCO) announced a new strategic partnership with the Biomedical Advanced Research and Development Authority under which the company will receive funding for developing of new infection drug.
CBM: 46.60 (+0.30), MDCO: 40.45 (-1.05), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Gilead to Stop GS-5745 Development for Ulcerative Colitis
Zacks Equity Research - Zacks Investment Research - Thu Sep 22, 6:51AM CDT
Gilead Sciences (GILD) announced that it will discontinue the combined phase II/III study on GS-5745 in patients with ulcerative colitis.
GILD: 81.37 (-0.15), BMY: 56.48 (+0.06), ANIK: 46.92 (-1.07), PCRX: 36.86 (-0.66)
Regeneron, Teva Collaborate to Develop Chronic Pain Drug
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 2:08PM CDT
Regeneron (REGN) and Teva have inked a deal for the development and commercialization of experimental NGF antibody, fasinumab, for chronic pain.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), ANIK: 46.92 (-1.07), REGN: 410.39 (+2.38)
Puma (PBYI) Neratinib's NDA Accepted for Review, Stock Up
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:51AM CDT
Puma Biotechnology (PBYI) announced that its New Drug Application for neratinib has been accepted for review by the FDA.
ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07), PBYI: 68.08 (+2.10)
Amgen (AMGN) Repatha Meets Endpoints in Phase III Study
Zacks Equity Research - Zacks Investment Research - Wed Sep 21, 9:47AM CDT
Amgen, Inc. (AMGN) announced positive top-line results from a phase III study evaluating the effect of its cholesterol-lowering medication, Repatha (evolocumab) on coronary artery disease (CAD) patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), AMGN: 174.80 (-0.82), ANIK: 46.92 (-1.07)
Vical Slumps, Cytomegalovirus Vaccine Fails in Phase II Study
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 3:16PM CDT
Vical (VICL) and Astellas reported disappointing top-line phase II data on cytomegalovirus vaccine candidate, ASP0113, in kidney transplant patients.
VICL: 3.25 (+0.06), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
BioDelivery Bunavail Gets Better Managed Care Positioning
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:42AM CDT
BioDelivery Sciences International, Inc. (BDSI) has secured improved positioning for Bunavail (buprenorphine and naloxone) under three new managed care contracts.
BDSI: 2.70 (+0.25), CBM: 46.60 (+0.30), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Sarepta Stock Nearly Doubles on FDA Approval for DMD Drug
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:13AM CDT
Sarepta (SRPT) announced that it gained an accelerated approval for its Duchenne muscular dystrophy (DMD) drug, Exondys 51 (eteplirsen), in the U.S.
BMRN: 97.40 (-0.05), ANIP: 66.64 (-0.17), SRPT: 57.83 (-3.14), ANIK: 46.92 (-1.07)
Bayer (BAYRY) Strives for Increased Sales & Earnings Growth
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 9:09AM CDT
Bayer (BAYRY) has set out encouraging growth and earnings targets across all its businesses at the "Meet Management" investor conference.
MON: 103.50 (-0.70), ANIP: 66.64 (-0.17), ANIK: 46.92 (-1.07)
Celgene Presents Efficacy & Safety Phase II Ozanimod Data
Zacks Equity Research - Zacks Investment Research - Tue Sep 20, 5:53AM CDT
Celgene (CELG) reported efficacy and safety data at 2 years from the phase II RADIANCE study on ozanimod in relapsing multiple sclerosis patients.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07), CELG: 109.43 (-1.14)
Ligand (LGND) Inks Deal with TeneoBio for OmniAb Technology
Zacks Equity Research - Zacks Investment Research - Mon Sep 19, 9:26AM CDT
Ligand Pharmaceuticals Incorporated (LGND) announced that it has entered into a worldwide license agreement with California-based TeneoBio, Inc.
EBS: 28.36 (-0.38), ANIP: 66.64 (-0.17), LGND: 115.78 (-2.38), ANIK: 46.92 (-1.07)
Qiagen: Molecular Diagnostics & Expansion Plans on Track
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:14AM CDT
On Sep 13, 2016, we issued an updated research report on Qiagen NV (QGEN).
HSKA: 54.46 (-0.22), ANIP: 66.64 (-0.17), QGEN: 26.66 (-0.21), ANIK: 46.92 (-1.07)
Novavax Tanks, RSV F Vaccine Disappoints in Two Studies
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:04AM CDT
Novavax (NVAX) announced disappointing top-line data from a couple of studies on RSV F Vaccine in older adults.
ANIP: 66.64 (-0.17), NVAX: 2.26 (+0.11), GERN: 2.20 (-0.02), ANIK: 46.92 (-1.07)
Teva/Intel Tie up for Huntington's Disease Technology Platform
Zacks Equity Research - Zacks Investment Research - Fri Sep 16, 8:01AM CDT
Teva (TEVA) is collaborating with Intel (INTC) to develop a wearable device and machine learning platform that can be used for the treatment of Huntington's disease.
ANIP: 66.64 (-0.17), TEVA: 51.47 (+0.24), INTC: 37.19 (-0.36), ANIK: 46.92 (-1.07)
Spectrum (SPPI) Down, Qapzola Fails to Impress FDA Panel
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 4:29PM CDT
Spectrum Pharmaceuticals' (SPPI) bladder cancer treatment Qapzola receives unfavorable recommendation from the FDA's advisory panel; stock down.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), SPPI: 4.72 (-0.09), ANIK: 46.92 (-1.07)
Glaxo (GSK) Publishes Phase III Data on Shingles Vaccine
Zacks Equity Research - Zacks Investment Research - Thu Sep 15, 9:27AM CDT
GlaxoSmithKline (GSK) reported that phase III study (ZOE-70) data on shingles vaccine candidate, Shingrix, were published in the New England Journal of Medicine.
ANIP: 66.64 (-0.17), GERN: 2.20 (-0.02), GSK: 43.42 (-0.16), ANIK: 46.92 (-1.07)
(0)
(0)